CoChat

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Open access
Strickler, John H, Cercek, Andrea, Siena, Salvatore, André, Thierry, Ng, Kimmie, Van Cutsem, Eric, Wu, Christina, Paulson, Andrew S, Hubbard, Joleen M, Coveler, Andrew L, Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon M, Lenz, Heinz-Josef, Ciombor, Kristen K, Elez, Elena, Bajor, David L, Cremolini, Chiara, Sanchez, Federico, Stecher, Michael, Feng, Wentao, Bekaii-Saab, Tanios S, Van Cutsem, Eric, Peeters, Marc, Van den Evnde, Marc, André, Thierry, Borg, Christophe, Sarabi, Matthieu, Ghiringhelli, Francois, Chibaudel, Benoist, Siena, Salvatore, Cremolini, Chiara, Zampino, Maria G., Elez, Elena, Keranen, Susana R., Salazar, Ramon, Alfonso, Pilar, Strickler, John H., Cercek, Andrea, Ng, Kimmie, Wu, Christina, Paulson, Andrew S., Hubbard, Joleen M., Coveler, Andrew L., Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon M., Lenz, Heinz-Josef, Ciombor, Kristen K., Bajor, David L., Bekaii-Saab, Tanios S., Gbolahan, Olumide, Boland, Patrick, Berg, Daniel, Sanchez, Federico, Goggins, Timothy, Saeed, Anwar, Burris, Howard, Bendell, Johanna, Outlaw, Darryl, Tafur, Isaac, Shergill, Ardaman, Catenacci, Daniel, Gong, Jun, Garrido-Laguna, Ignacio, Finley, Gene, Weinberg, Benjamin, Shields, Anthony, Philip, Philip, Turk, Anita, Nguyen, Anthony, Braiteh, Fadi, Patel, Vijay, Harwin, William, Anderson, Ian, Kundra, Ajay, Chen, Christopher, Ford, James, Kundranda, Madappa, Nguyen, Danny, Ratnam, Suresh, Richards, Donald, Nallapareddy, Sujatha, Beeram, Sridhar, McKenney, Scott, Shao, Spencer · 2023 · The Lancet Oncology

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.Methods MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing.Findings Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47-64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7-49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression.Interpretation Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.Funding Seagen and Merck & Co.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00150-x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. Pheneger, 2009, In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2, Cancer Res, 69

Cited by

See all 277

Metadata

Authors
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Elez, E., Bajor, D. L., Cremolini, C., Sanchez, F., Stecher, M., Feng, W., Bekaii-Saab, T. S., Van Cutsem, E., Peeters, M., Van den Evnde, M., André, T., Borg, C., Sarabi, M., Ghiringhelli, F., Chibaudel, B., Siena, S., Cremolini, C., Zampino, M. G., Elez, E., Keranen, S. R., Salazar, R., Alfonso, P., Strickler, J. H., Cercek, A., Ng, K., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Bajor, D. L., Bekaii-Saab, T. S., Gbolahan, O., Boland, P., Berg, D., Sanchez, F., Goggins, T., Saeed, A., Burris, H., Bendell, J., Outlaw, D., Tafur, I., Shergill, A., Catenacci, D., Gong, J., Garrido-Laguna, I., Finley, G., Weinberg, B., Shields, A., Philip, P., Turk, A., Nguyen, A., Braiteh, F., Patel, V., Harwin, W., Anderson, I., Kundra, A., Chen, C., Ford, J., Kundranda, M., Nguyen, D., Ratnam, S., Richards, D., Nallapareddy, S., Beeram, S., McKenney, S., & Shao, S.
Affiliations
Seagen (United States) (US)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-05
Volume
24
Issue
5
Pages
496-508
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4367670315
Cited by
259
References
23
Citations by year
2026: 61 · 2025: 75 · 2024: 100 · 2023: 23
FWCI
31.59
Type
journal article
Language
en
Open access
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
  • Lirias (KU Leuven) (submittedVersion)
Funders
Merck
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
tucatinib, trastuzumab, HER2-positive colorectal cancer, RAS wild-type, metastatic colorectal cancer, chemotherapy-refractory disease, HER2-targeted therapy, combination therapy, objective response rate, safety, trastuzumab resistance
MeSH terms
Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Diarrhea, Female, Humans, Male, Middle Aged, Oxazoles, Pyridines, Quinazolines, Rectal Neoplasms, Cohort Studies, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00150-x
The paper
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., Fountzilas, C., Kardosh, A., Kasi, P. M., Lenz, H.-J., Ciombor, K. K., Elez, E., Bajor, D. L., Cremolini, C., Sanchez, F., . . . Shao, S. (2023). Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00150-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.